Over the last decade, there have been numerous developments and changes in treatment
practices for the management of patients with immune thrombocytopenia (ITP). This article is …

Eltrombopag is currently the only US Food and Drug Administration–approved
thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia (ITP) …

Immune thrombocytopenia (ITP) has historically been thought to occur in 2 distinct forms:
childhood ITP and adult ITP. This division is based largely on the presumption that …

Immune thrombocytopenia (ITP), resulting from antibody-mediated platelet destruction
combined with impaired platelet production, is a rare cause of thrombocytopenia in both …

In primary chronic immune thrombocytopenia, long‐term response to splenectomy, with 60%
of patients enjoying a treatment‐free life, is higher when compared with rituximab and …

Primary immune thrombocytopenia (ITP) is a complex autoimmune disease whose hallmark
is a deregulation of cellular and humoral immunity leading to increased destruction and …

Immune thrombocytopenia (ITP) is an autoimmune bleeding disorder with isolated
thrombocytopenia and hemorrhagic risk. While many children with ITP can be safely …

Evidence-based medicine is growing in immune thrombocytopenia (ITP), but solid clinical
data are still lacking in many areas. A majority of children has self-limited ITP, but chronic …

Newly diagnosed immune thrombocytopenia (ITP) is a relatively common disorder of
childhood that does not require an exhaustive laboratory workup for diagnosis. A history and …

Immune thrombocytopenia (ITP) is an autoimmune bleeding disorder with isolated
thrombocytopenia and risk of hemorrhage. Treatment with eltrombopag increases and …